GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in insulin secretion and a lowering of glucagon secretion; in addition, they lower body weight and systolic blood pressure and increase heart rate. Using a new monoclonal antibody for immunohistochemistry, we detected GLP-1 receptor (GLP-1R) in important target organs in humans and monkeys. In the pancreas, GLP-1R was predominantly localized in β-cells with a markedly weaker expression in acinar cells. Pancreatic ductal epithelial cells did not express GLP-1R. In the kidney and lung, GLP-1R was exclusively expressed in smooth muscle cells in the walls of arteries and arterioles. In the heart, GLP-1R was localized in myocytes of the sinoatrial node. In the gastrointestinal tract, the highest GLP-1R expression was seen in the Brunner's gland in the duodenum, with lower level expression in parietal cells and smooth muscle cells in the muscularis externa in the stomach and in myenteric plexus neurons throughout the gut. No GLP-1R was seen in primate liver and thyroid. GLP-1R expression seen with immunohistochemistry was confirmed by functional expression using in situ ligand binding with 125I-GLP-1. In conclusion, these results give important new insight into the molecular mode of action of GLP-1 analogs by identifying the exact cellular localization of GLP-1R.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, GLP-1R is present beyond the confines of the pancreas and extends to a multitude of organs and tissues throughout the body. Its extensive distribution and involvement in diverse physiological processes emphasize the important role of GLP-1R beyond the regulation of glucose metabolism.38–40”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [38]
In the citing paper
“Nevertheless, studies using antibodies that appear to be specific for this receptor are consistent with results from gene expression studies, demonstrating staining for the GLP-1 receptor in human and primate kidney in juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“despite only modest expression of the GLP-1 receptor in the kidney”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [8]
In the citing paper
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [74]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 1×
“This strain of mice is on a C57BL background and is derivedfromthepreviouslydescribedGLP-1Rknockoutstrain(20) custom bred by Novo Nordisk A/S at Taconic.”
MethodBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“In situ ligand binding for functional GLP-1R localization was performed as described previously, apart from the use of (125)IGLP-1 (7–36) (NEX3080; PerkinElmer) instead of (125)I-exendin (9–39) (21, 22).”
MethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“GLP-1 has been shown to inhibit gastric acid secretion and gastric motility (36), and these effects fit well with our GLP-1R IHC findings.”
ResultTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 5×
“1284 Pyke et al Immunolocalization of GLP-1R Endocrinology, April 2014, 155(4):1280–1290”
BackgroundInfluentialSelf-citationCentral administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 4×
“The low-level GLP-1R expression in acinar cells reported in this study corresponds well with previous reports using ISLB on normal human pancreas (8, 25).”
BackgroundResultInfluentialWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Cited by
Items 301–400 of 880
Giblett, J. P., Clarke, S. J., Dutka, D. P., & Hoole, S. P. (2016) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.011 · Cited by 35
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 40
Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity
Kimura, T., Obata, A., Shimoda, M., Shimizu, I., Xavier, G. D. S., Okauchi, S., Hirukawa, H., Kohara, K., Mune, T., Moriuchi, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28849-1 · Cited by 37
Katsurada, K., Nandi, S. S., Sharma, N. M., Zheng, H., Liu, X., & Patel, K. P. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00028.2019 · Cited by 37
Fernandez, E. D. T., Huffman, A. M., Syed, M., Romero, D. G., & Cardozo, L. L. Y. (2019) · Endocrinology · doi:10.1210/en.2019-00450 · Cited by 37
Kaneko, S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.10 · Cited by 59
“Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry.”
BackgroundMethodHepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target
Milani, I., Codini, M., Guarisco, G., Chinucci, M., Gaita, C., Leonetti, F., & Capoccia, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910795 · Cited by 44
“Regarding the localization of the GLP-1R in the liver, some studies suggest the absence of GLP-1 receptors in hepatocytes [115,116], while others indicate their presence [117–120].”
BackgroundAnand, U., Yiangou, Y., Akbar, A., Quick, T., MacQuillan, A. H. F., Fox, M., Sinisi, M., Korchev, Y. E., Jones, B. J., Bloom, S. R., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198024 · Cited by 35
Farokhnia, M., Fede, S. J., Grodin, E. N., Browning, B. D., Crozier, M. E., Schwandt, M. L., Hodgkinson, C. A., Momenan, R., & Leggio, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-17190-3 · Cited by 32
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
Direct effect of incretin hormones on glucose and glycerol metabolism and hemodynamics
Karstoft, K., Mortensen, S. P., Knudsen, S. H., & Solomon, T. P. J. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00520.2014 · Cited by 32
Packer, M. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1185 · Cited by 35
Chalmer, T., Almdal, T. P., Vilsbøll, T., & Knop, F. K. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.975205 · Cited by 31
“Native GLP-1 exerts its effects via activation of GLP-1 receptors, which are located in several tissues in the human body, including the pancreas [6].”
BackgroundInfluentialSloop, K. W., Briere, D. A., Emmerson, P. J., & Willard, F. S. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00009 · Cited by 31
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“For example, recent work suggests that cardiac GLP-1 receptor expression may be localized to atrial tissue, sinoatrial node and vasculature, with some species variation (Kim et al., 2013; Pyke et al., 2014; Richards et al., 2014), and that earlier reports of more ubiquitous expression may be questionable because of po…”
BackgroundMechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000894 · Cited by 34
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 44
Noureddin, M., Rinella, M. E., Taub, R. A., Labriola, D., Camacho, R. C., Alkhouri, N., Loomba, R. S., & Bansal, M. B. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70382 · Cited by 44
“Because GLP-1 receptors are not expressed in liver [24], the potential mechanism of action in MASH relates to indirect actions to reduce body weight, insulin resistance, and metabolic dysfunction [25].”
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 36
“Generation of novel antibodies [23] and Glp1r promoter-Cre transgenic mice facilitating activation of reporter genes in Glp1r-expressing tissues [24] are potential strategies to overcome this problem.”
BackgroundJorsal, A., Wiggers, H., Holmager, P., Nilsson, B., Nielsen, R., Boesgaard, T. W., Kumme, A., Møller, J. E., Videbæk, L., Kistorp, C., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004885 · Cited by 31
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Pieters, I. C., Cahen, D. L., Diamant, M., & van Raalte, D. H. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009579 · Cited by 30
Zhang, N., Tao, J., Gao, L., Bi, Y., Li, P., Wang, H., Zhu, D., & Feng, W. (2020) · BioMed Research International · doi:10.1155/2020/2947549 · Cited by 31
Singh, A. K., Gangopadhyay, K. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1736041 · Cited by 33
Molecular chaperones and G protein-coupled receptor maturation and pharmacology
Tao, Y. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110862 · Cited by 33
Wang, T., Wang, F., Zhou, J., Tang, H., & Giovenale, S. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2804 · Cited by 35
“GLP-1 receptors have also been located in the sinoatrial node [144].”
BackgroundSitagliptin use and thyroid cancer risk in patients with type 2 diabetes
Tseng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.8399 · Cited by 38
“could not similarly demonstrate GLP-1R in normal thyroid tissues in either monkeys or humans by using a new monoclonal antibody [8], this could not exclude the expression of GLP-1R in pre-malignant and malignant thyroid cells.”
BackgroundClinical potential of treatment with semaglutide in type 2 diabetes patients
Røder, M. E. (2019) · Drugs in Context · doi:10.7573/dic.212585 · Cited by 37
Katsurada, K., Nandi, S. S., Zheng, H., Liu, X., Sharma, N. M., & Patel, K. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01029-0 · Cited by 32
Petersen, K. M., Bøgevig, S., Riis, T., Andersson, N. W., Dalhoff, K., Holst, J. J., Knop, F. K., Faber, J. O., Petersen, T. S., & Christensen, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016828 · Cited by 32
“26 The receptor for GLP-1 is expressed in human myocardium and perhaps also in the sinoatrial node, 25,27 and administration of GLP-1 (and GLP-1 analogs) increases heart rate and cardiac output.”
Bakbak, E., Terenzi, D. C., Trac, J. Z., Teoh, H., Quan, A., Glazer, S. A., Rotstein, O. D., Al-Omran, M. A., Verma, S., & Hess, D. A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09669-7 · Cited by 32
GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Chen, Y., Xu, Y.-N., Ye, C.-Y., Feng, W., Zhou, Q., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00836-9 · Cited by 36
“Since there is still controversy about the presence [49, 50] or absence [51, 52] of GLP-1R within hepatocytes, the direct or indirect role of GLP-1 and its mimetics on hepatic glucolipid metabolism remains to be fully elucidated.”
BackgroundFerreira, J. P., Sharma, A., Vasques‐Nóvoa, F., Angélico‐Gonçalves, A., Leite, A. R., Borges‐Canha, M., Carvalho, D. M., Packer, M., Zannad, F. M., Leite-Moreira, A. F., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2660 · Cited by 32
“Furthermore, the GLP-1 receptor, expressed in cardiomyocytes and sinoatrial node cells, signals through a cAMP-dependent pathway which may induce intracellular calcium overload that may be deleterious in HF patients, particularly those with advanced HFrEF (which were excluded from Harmony Outcomes).(3,26,27) In this r…”
BackgroundStructural insight into antibody-mediated antagonism of the Glucagon-like peptide-1 Receptor
Hennen, S., Kodra, J. T., Soroka, V., Krogh, B. O., Wu, X., Kaastrup, P., Ørskov, C., Rønn, S. G., Schluckebier, G., Barbateskovic, S., et al. (2016) · Scientific Reports · doi:10.1038/srep26236 · Cited by 33
“The binding properties of mAb 3F52 to GLP-1R were characterized in a competition binding assay using 125I-GLP-1(7-37)-OH as the tracer on cell membranes expressing the human GLP-1R.”
InfluentialSelf-citationIncretin-based therapy and pancreatitis: accumulating evidence and unresolved questions
Saisho, Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.02.24 · Cited by 31
“Recent studies have shown that the GLP-1 receptor is weakly expressed in acinar cells (17) and, in mice, GLP-1 increases amylase secretion from acinar cells (18,19).”
BackgroundRenoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 36
Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury
Chong, L., Liu, Y., He, J. N., Mu, R., Di, Y., Shen, N., Liu, X., Gao, X., Wang, J., Chen, T., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00789 · Cited by 30
Vascular repair and regeneration in cardiometabolic diseases
Hess, D. A., Verma, S., Bhatt, D. L., Bakbak, E., Terenzi, D. C., Puar, P., & Cosentino, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab758 · Cited by 31
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 39
Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications
Afşar, B., Hornum, M., Afşar, R. E., Ertuğlu, L. A., Ortíz, A., Covic, A. C., van Raalte, D. H., Cherney, D. Z. I., & Kanbay, M. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.02.016 · Cited by 30
Evaluating the glucagon-like peptide-1 receptor in managing asthma
Wu, A. Y., Cahill, K. N., Toki, S., & Peebles, R. S. (2021) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000797 · Cited by 30
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 35
“GLP-1R is also not expressed in the liver (Pyke et al. 2014).”
BackgroundInfluentialDai, F. F., Bhattacharjee, A., Liu, Y., Batchuluun, B., Zhang, M., Wang, X. S., Huang, X., Luu, L., Zhu, D. Y., Gaisano, H. Y., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.648592 · Cited by 29
Glucagon‐like peptide‐1 drives energy metabolism on the synaptic highway
Liu, J., & Pang, Z. P. (2016) · The FEBS Journal · doi:10.1111/febs.13785 · Cited by 28
The GLP-1 receptor in airway inflammation in asthma: a promising novel target?
Wu, A. Y., & Peebles, R. S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1971973 · Cited by 34
“Beyond the pancreas, GLP-1R is expressed abundantly in human lung, heart, brain, kidney, and GI tract [3].”
BackgroundPardridge, W. M. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1276376 · Cited by 30
Vinet, L., Lamprianou, S., Babič, A., Lange, N., Thorel, F., Herrera, P. L., Montet, X., & Meda, P. (2014) · Diabetologia · doi:10.1007/s00125-014-3442-2 · Cited by 28
“The data provide a significant step towards the validation of a probe monitoring the effect of candidate treatments in a pre-clinical setting, assuming that the expression of GLP-1rs is not altered under different glycaemic conditions [43].”
InfluentialSavignano, F. A., Crajoinas, R. O., Pacheco, B. P. M., Campos, L. C. G., Shimizu, M. H. M., Seguro, A. C., & Girardi, A. C. C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.054 · Cited by 31
Intestinal Incretins and the Regulation of Bone Physiology
Ramsey, W. A., & Isales, C. M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-66653-2_2 · Cited by 29
Kang, Z., Zeng, J., Zhang, T., Lin, S., Gao, J., Jiang, C., Fan, R., & Yin, D. (2019) · Cell Biology International · doi:10.1002/cbin.11184 · Cited by 32
“Studies have reported that GLP‐1R is expressed in the proximal convoluted tubules, glomerulus, and renal vasculature in mouse, rat, monkey, and human tissues (Crajoinas et al., 2011; Fujita et al., 2014; Pyke et al., 2014; Jensen et al., 2015).”
Jensen, E. P., Møller, S., Hviid, A. V., Veedfald, S., Holst, J. J., Pedersen, J., Ørskov, C., & Sorensen, C. M. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00579.2019 · Cited by 27
Self-citationDorsolateral septum GLP-1R neurons regulate feeding via lateral hypothalamic projections
Lu, Y., Wang, L., Luo, F., Savani, R. H., Rossi, M. A., & Pang, Z. P. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101960 · Cited by 28
“GLP-1 actions are mediated by GLP-1R, which is widely expressed in both the periphery [62] and the brain, including the dLS, LHA, and paraventricular hypothalamic nucleus, among other regions.”
Gut hormones and bone homeostasis: potential therapeutic implications
Bouvard, B., & Mabilleau, G. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01000-z · Cited by 29
“However, GLP1R is not expressed by human thyroid C cells 92 and as such,”
Binding sites and design strategies for small molecule GLP-1R agonists
Zhang, H., Wu, T., Wu, Y., Peng, Y., Wei, X. H., Lu, T., & Jiao, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116632 · Cited by 29
GLP-1R Agonists and Endothelial Dysfunction: More Than Just Glucose Lowering?
Lovshin, J. A., & Cherney, D. Z. I. (2015) · Diabetes · doi:10.2337/db15-0366 · Cited by 32
“Possible explanations for differing results between GLP-1(7-36), GLP-1R agonists, and DPP-4 inhibitors include 1) differences in study design (T2D vs.”
BackgroundResultInfluentialTargeting the gastrointestinal tract to treat type 2 diabetes
Bauer, P. V., & Duca, F. A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0056 · Cited by 29
Mayer, F., Gunawan, A. L., Tso, P., & Aponte, G. W. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00189.2019 · Cited by 32
Asmar, A., Cramon, P. K., Asmar, M., Simonsen, L., Sorensen, C. M., Madsbad, S., Hartmann, B., Holst, J. J., Hovind, P., Jensen, B. L., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa643 · Cited by 27
Jensterle, M., Rizzo, M., & Janež, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020902 · Cited by 35
“No expression occurred in the liver and the thyroid [23].”
BackgroundInfluentialKing, N. E., & Brittain, E. L. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12028 · Cited by 30
“120–123 The GLP1 receptor is expressed in multiple tissues, including the heart and the smooth muscle cells of the main pulmonary artery branches in primates.(124) GLP1 agonists reduce inflammatory signaling at a cellular level, and animal studies show GLP1 agonists reduce infarct size and improve outcomes in the sett…”
BackgroundKirk, R. K., Pyke, C., von Herrath, M. G., Hasselby, J. P., Pedersen, L., Mortensen, P. G., Knudsen, L. B., & Coppieters, K. T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12879 · Cited by 28
“Staining of GLP-1R, both in single- and double-labelling protocols, showed immunoreactivity patterns consistent with those observed in a previous study of 22 normal and diabetic human pancreas samples.(17) In double-labelling fluorescence of GLP-1R combined with insulin a marked co-localization of the two proteins was…”
ResultInfluentialSelf-citationNyström, T., Santos‐Pardo, I., Hedberg, F., Wardell, J., Witt, N., Cao, Y., Bojö, L., Nilsson, B., & JENDLE, J. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00325 · Cited by 27
“Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling.”
BackgroundInvestigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
“It binds to the GLP-1 receptor (GLP-1R) which is expressed on pancreatic islet α-cells and β-cells and many other tissues including the peripheral and central nervous system [28,29].”
BackgroundGLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Chen, T., Hu, E.-H., Chen, D., Lin, Y., Chou, T., Lin, M., Yang, N., Wang, C., Hung, M., & Tsai, M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30952 · Cited by 37
Amouyal, C., & Andreelli, F. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5908656 · Cited by 25
Gamble, J., Donnan, J. R., Chibrikov, E., Twells, L., Midodzi, W. K., & Majumdar, S. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-33483-y · Cited by 26
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 34
“However, the precise intracellular localization of GLP-1R remains to be fully elucidated [18,19].”
BackgroundMethodLiraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00942-2 · Cited by 25
Hunt, B., Kragh, N., McConnachie, C. C., Valentine, W. J., Rossi, M. C., & Montagnoli, R. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.354 · Cited by 24
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry
López-Ojeda, W., & Hurley, R. A. (2024) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20230226 · Cited by 31
Hassan, N. F., Ragab, D., Ibrahim, S. G., Elgalil, M. M. A., Abd-El-Hamid, A. H., Hamed, D. M., William, M. M., & Salem, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112308 · Cited by 28
Peptide–Oligonucleotide Conjugation: Chemistry and Therapeutic Applications
Malinowska, A. L., Huynh, H. L., & Bose, S. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46100655 · Cited by 25
Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes
Dejgaard, T. F., Johansen, N. B., Frandsen, C. S., Asmar, A., Tarnow, L., Knop, F. K., Madsbad, S., & Andersen, H. U. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12841 · Cited by 26
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
Jiménez, D. L., Cherney, D. Z. I., Bjornstad, P., Castilla‐Guerra, L., & Miramontes‐González, J. P. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00384.2017 · Cited by 27
Bjørnholm, K. D., Skovsted, G. F., Mitgaard‐Thomsen, A., Rakipovski, G., Tveden‐Nyborg, P., Lykkesfeldt, J., & Povlsen, G. K. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13486 · Cited by 24
Exendin-4 Promotes Schwann Cell Survival/Migration and Myelination In Vitro
Takaku, S., Tsukamoto, M., Niimi, N., Yako, H., & Sango, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062971 · Cited by 24
“GLP-1Rs are localized at not only the pancreas but also the extra-pancreatic tissues, including the nervous system [3].”
BackgroundKim, D., Park, M.-J., Heo, Y., & Park, S.-H. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.08.009 · Cited by 27
May, A. T., Crowe, M. S., Blakeney, B. A., Mahavadi, S., Wang, H., Grider, J. R., & Murthy, K. S. (2018) · Peptides · doi:10.1016/j.peptides.2018.11.007 · Cited by 31
“In the GI tract of monkey, expression of GLP-1R protein has been demonstrated in the Brunner’s gland epithelium of the duodenum and in the myenteric nerve plexus and smooth muscle cells; staining was prominent in the epithelium whereas staining in myenteric plexus and smooth muscle was low-intensity [45].”
BackgroundZhou, X., Huang, C.-H., Lao, J., Pocai, A., Forrest, G., Price, O., Roy, S., Kelley, D. E., Sullivan, K. A., & Forrest, M. J. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0194-3 · Cited by 23
“GLP-1 receptor agonism reduces NHE3 activity and inhibits sodium re-absorption in renal proximal tubule cells [31,32].”
BackgroundBangshaab, M., Cruz, A. G., Huynh, K. D., Knudsen, J. S., Arcanjo, D. D. R., Petersen, A. G., Rungby, J., Gejl, M., & Simonsen, U. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14534 · Cited by 27
“In the cardiovascular system, the GLP-1 receptor is expressed in smooth muscle cells, the sinoatrial node (Pyke et al., 2014), the myocardium and microvascular endothelium (Ban et al.”
BackgroundLiu, Q., Garg, P., Hasdemir, B., Wang, L., Tuscano, E., Sever, E. N., Rivera, E. K., Hernandez, A. G. L., Yuan, T. Z., Kwan, E., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1893425 · Cited by 24
Bulum, T. (2022) · Biomedicines · doi:10.3390/biomedicines10102586 · Cited by 31
Haddock, B., Kristensen, K. B., Tayyab, M., Larsson, H. B. W., Lindberg, U., Vestergaard, M., Francis, S., Jensen, B. L., Andersen, U. B., & Asmar, A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027712 · Cited by 23
Smits, M. M., & Holst, J. J. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3699 · Cited by 26
“20,21 However, as discussed more thoroughly in a later section, many experts wonder whether GLP ‐ 1 actually stimulates its receptor directly on the target organs, given the relatively low systemic levels, or whether it mainly acts indirectly through stimulation of the (enteric) nervous system.”
BackgroundPreventing new-onset heart failure: Intervening at stage A
Upadhya, B., Hegde, S., Tannu, M., Stacey, R. B., Kalogeropoulos, A. P., & Schocken, D. D. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100609 · Cited by 27
“GLP1RAs have a positive chronotropic effect, causing an increase in heart rate by activating adenylate cyclase in cardiac myocytes of the sinoatrial node, which can deleteri-ously affect HF [101].”
BackgroundGlucagon-Like Peptide 1 Receptor Agonists and Asthma Exacerbations: Which Patients Benefit Most?
Wang, T., Keil, A. P., Buse, J. B., Keet, C. A., Kim, S., Wyss, R., Pate, V., Jonsson‐Funk, M. L., Pratley, R. E., Kvist, K., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202309-836oc · Cited by 25
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
“Interestingly, GLP-1Rs are abundantly expressed not only in the pancreas and gastrointestinal tract but also in other organs, such as the lung [247].”
Liu, H., Schultz, C. G., Blasio, M. J. D., Peura, A. M., Heinemann, G. K., Harryanto, H., Hunter, D., Wooldridge, A. L., Kind, K. L., Giles, L. C., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00487.2014 · Cited by 23
“These responses suggest that the receptor is present in gastrointestinal and/or brain sites and pancreas in early life in sheep, consistent with expression patterns in humans and rodents, where the GLP-1 receptor is expressed in gastrointestinal tract, brain, heart, kidney, lung, and pancreatic islets, particularly -c…”
BackgroundBalk-Møller, E., Windeløv, J. A., Svendsen, B., Hunt, J., Ghiasi, S. M., Sørensen, C. M., Holst, J. J., & Kissow, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz034 · Cited by 22
“GLP-1 acts by binding to GLP-1R, which is found in the brain, heart, stomach, intestine, kidney, and nerves (6, 8-12).”
BackgroundMulti-organ Coordination of Lipoprotein Secretion by Hormones, Nutrients and Neural Networks
Stahel, P., Xiao, C., Nahmias, A., Tian, L., & Lewis, G. F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab008 · Cited by 26
Expanded LUXendin Color Palette for GLP1R Detection and Visualization In Vitro and In Vivo
Ast, J., Novak, A. N., Podewin, T., Fine, N. H. F., Jones, B. J., Tomás, A., Birke, R., Roßmann, K., Mathes, B., Eichhorst, J., et al. (2022) · JACS Au · doi:10.1021/jacsau.2c00130 · Cited by 25
Kimura, T., Katakura, Y., Shimoda, M., Kawasaki, F., Yamabe, M., Tatsumi, F., Matsuki, M., Iwamoto, Y., Anno, T., Fushimi, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15258 · Cited by 28
“31,32 Therefore, the primary mechanisms for the effects of GLP-1RA on the liver are thought to involve multiple pathways, including portal and peripheral insulin and glucagon concentrations, as well as a reduction of adipose tissue lipotoxicity with weight loss.”
BackgroundGlucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
HOFFMAN, S. S., & Adeli, K. (2024) · Medical Review · doi:10.1515/mr-2024-0011 · Cited by 27
“GLP-1R mRNA has also been found in acid secreting parietal cells [70] where they may block gastric acid secretion and in specialized mucus secreting cells in the proximal duodenum called Brunners glands [71].”
BackgroundPhysiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake
Elliott, J. A., Reynolds, J. V., le Roux, C. W., & Docherty, N. G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1245140 · Cited by 24
“receptors may explain small but significant increases in heart rate associated with administration of GLP-1 or its analog [192,193].”
BackgroundHussien, N. I., Sorour, S. M., Elkerdasy, H., & Abdelrahman, B. A. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12944 · Cited by 22
Liljedahl, L., Pedersen, M. H., McGuire, J. N., & James, P. (2019) · Physiological Reports · doi:10.14814/phy2.13994 · Cited by 21
“In the kidney, the GLP-1R has been detected in smooth muscle cells in the vascular walls of arteries and arterioles in primates (Pyke et al. 2014) and rodents (Jensen et al.”
BackgroundChrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 27
Next-generation therapeutics for diabetic kidney disease
Yi, T. W., Sridhar, V. S., Scott, J., Nardone, M., & Cherney, D. Z. I. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01042-0 · Cited by 29
Metadata
- Authors
- Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Department of Diabetes Structural Biology (S.R.-R.), Novo Nordisk, 2880 Bagsværd, Denmark
- Rigshospitalet (DK)
- Corresponding author
- Knudsen, Lotte Bjerre
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2014-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 1280-1290
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W1979288606
- Cited by
- 876
- References
- 37
- Citations by year
- 2026: 99 · 2025: 91 · 2024: 103 · 2023: 56 · 2022: 70 · 2021: 64 · 2020: 64 · 2019: 57 · 2018: 60 · 2017: 64 · 2016: 61 · 2015: 58 · 2014: 27
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Endocrinology (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, glucagon-like peptide-1, receptor localization, type 2 diabetes, GLP-1 analogues, pancreatic beta cells, sinoatrial node, Brunner's glands, myenteric neurons, smooth muscle cells, kidney, heart, gastrointestinal tract, receptor expression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Exenatide, Insulin Secretion, Animals, Haplorhini, Antibodies, Monoclonal, Blood Pressure, Body Weight, Cell Line, Duodenum, Glucagon, Cricetinae, Heart Rate, Humans, Insulin, Ligands, Mice, Inbred C57BL, Peptides, Protein Binding, Tissue Distribution, Transfection, Venoms, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.